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Summary
Background The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer 
with the addition of bevacizumab to standard chemotherapy, with the greatest eff ect in patients at high risk of disease 
progression. We report the fi nal overall survival results of the trial.
Methods ICON7 was an international, phase 3, open-label, randomised trial undertaken at 263 centres in 11 countries 
across Europe, Canada, Australia and New Zealand. Eligible adult women with newly diagnosed ovarian cancer that 
was either high-risk early-stage disease (International Federation of Gynecology and Obstetrics [FIGO] stage I–IIa, 
grade 3 or clear cell histology) or more advanced disease (FIGO stage IIb–IV), with an Eastern Cooperative Oncology 
Group performance status of 0–2, were enrolled and randomly assigned in a 1:1 ratio to standard chemotherapy (six 
3-weekly cycles of intravenous carboplatin [AUC 5 or 6] and paclitaxel 175 mg/m² of body surface area) or the same 
chemotherapy regimen plus bevacizumab 7·5 mg per kg bodyweight intravenously every 3 weeks, given concurrently 
and continued with up to 12 further 3-weekly cycles of maintenance therapy. Randomisation was done by a 
minimisation algorithm stratifi ed by FIGO stage, residual disease, interval between surgery and chemotherapy, and 
Gynecologic Cancer InterGroup group. The primary endpoint was progression-free survival; the study was also 
powered to detect a diff erence in overall survival. Analysis was by intention to treat. This trial is registered as an 
International Standard Randomised Controlled Trial, number ISRCTN91273375.
Findings Between Dec 18, 2006, and Feb 16, 2009, 1528 women were enrolled and randomly assigned to receive 
chemotherapy (n=764) or chemotherapy plus bevacizumab (n=764). Median follow-up at the end of the trial on 
March 31, 2013, was 48·9 months (IQR 26·6–56·2), at which point 714 patients had died (352 in the chemotherapy 
group and 362 in the bevacizumab group). Our results showed evidence of non-proportional hazards, so we used the 
diff erence in restricted mean survival time as the primary estimate of eff ect. No overall survival benefi t of bevacizumab 
was recorded (restricted mean survival time 44·6 months [95% CI 43·2–45·9] in the standard chemotherapy group vs 
45·5 months [44·2–46·7] in the bevacizumab group; log-rank p=0·85). In an exploratory analysis of a predefi ned 
subgroup of 502 patients with poor prognosis disease, 332 (66%) died (174 in the standard chemotherapy group and 
158 in the bevacizumab group), and a signifi cant diff erence in overall survival was noted between women who 
received bevacizumab plus chemotherapy and those who received chemotherapy alone (restricted mean survival time 
34·5 months [95% CI 32·0–37·0] with standard chemotherapy vs 39·3 months [37·0–41·7] with bevacizumab; 
log-rank p=0·03). However, in non-high-risk patients, the restricted mean survival time did not diff er signifi cantly 
between the two treatment groups (49·7 months [95% CI 48·3–51·1]) in the standard chemotherapy group vs 
48·4 months [47·0–49·9] in the bevacizumab group; p=0·20). An updated analysis of progression-free survival 
showed no diff erence between treatment groups. During extended follow-up, one further treatment-related grade 3 
event (gastrointestinal fi stula in a bevacizumab-treated patient), three grade 2 treatment-related events (cardiac 
failure, sarcoidosis, and foot fracture, all in bevacizumab-treated patients), and one grade 1 treatment-related event 
(vaginal haemorrhage, in a patient treated with standard chemotherapy) were reported.
Interpretation Bevacizumab, added to platinum-based chemotherapy, did not increase overall survival in the study 
population as a whole. However, an overall survival benefi t was recorded in poor-prognosis patients, which is 
concordant with the progression-free survival results from ICON7 and GOG-218, and provides further evidence 
towards the optimum use of bevacizumab in the treatment of ovarian cancer.
Funding The National Institute for Health Research through the UK National Cancer Research Network, the Medical 
Research Council, and Roche.
Copyright © Oza et al. Open Access article distributed under the terms of CC BY.
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Introduction
Ovarian cancer is the seventh most common cancer 
worldwide, with 238 700 new cases and 151 900 deaths in 
2012.1 The prognosis of the disease remains poor: the 
European mean age-standardised 5-year survival was only 
37·6% for women diagnosed between 2000 and 2007.2
Until 2011, the international standard of care for women 
with advanced or poor-prognosis early-stage ovarian 
cancer mainly consisted of debulking surgery followed by 
chemotherapy with carboplatin and paclitaxel.3 Since 
then, modulation of VEGF has moved from a theoretical 
concept4 to a key component of treatment. Two large-scale 
phase 3 randomised trials, GOG-218 and ICON7, both 
undertaken in fi rst-line settings, showed that the addition 
of the anti-VEGF monoclonal antibody, bevacizumab, to 
conventionally administered carboplatin and paclitaxel 
chemotherapy signifi cantly improved progression-free 
survival.5,6 Two further randomised trials in recurrent 
ovarian cancer have shown signifi cant improvement in 
progression-free survival through the addition of 
bevacizumab to conventionally administered carboplatin 
and gemcitabine chemotherapy both in the platinum-
sensitive and platinum-resistant relapsed setting.7,8 These 
data were used to support bevacizumab licensing through 
the European Medicines Agency for use in the fi rst-line 
setting for patients with at least International Federation 
of Gynecology and Obstetrics (FIGO) stage IIIB disease 
(according to 1988 staging criteria), at fi rst recurrence for 
patients with platinum-sensitive disease not previously 
treated with bevacizumab or other VEGF-targeted drugs, 
and in the setting of platinum-resistant recurrence 
combined with paclitaxel, topotecan, or pegylated 
liposomal doxorubicin.9 Bevacizumab has also been 
approved in the platinum-refractory setting by the US 
Food and Drug Administration.10
The GOG-218 trial,5 which enrolled 1873 patients with 
FIGO stage III–IV ovarian cancer with macroscopic 
residual disease after primary surgery, showed a 
signifi cant improvement in progression-free survival with 
the addition of bevacizumab (hazard ratio [HR] 0·72, 
95% CI 0·63–0·82; p<0·001). Patients received treatment 
with carboplatin and paclitaxel chemotherapy, and either 
concurrent bevacizumab 15 mg per kg every 3 weeks 
followed by up to 16 cycles of maintenance bevacizumab 
(at the same dose) or placebo for the same duration, all 
administered intravenously. The ICON7 trial,6 which was 
done in a patient population that included those with 
poor-prognosis, early-stage disease and those with 
optimally or suboptimally debulked advanced disease, 
showed improved progression-free survival in patients 
receiving bevacizumab, with restricted mean progression-
free survival over 36 months of 20·3 months on standard 
chemotherapy and 21·8 months with bevacizumab 
(HR 0·81, 95% CI 0·70–0·94; p=0·004). An increased 
eff ect was noted in patients at high risk of disease 
progression, a similar group to the GOG-218 study 
population, with restricted mean progression-free survival 
after 42 months’ follow-up of 14·5 months in the standard 
chemotherapy group and 18·1 months in the bevacizumab 
group (HR 0·73, 95% CI 0·60–0·93; p=0·002).
To fully assess a new treatment, the eff ect on overall 
survival as well as progression-free survival must be 
known. ICON7 was designed with a progression-free 
survival primary endpoint but was also powered to detect 
an overall survival improvement. At the time of the 
primary progression-free survival analysis, overall 
survival data were immature in both ICON7 and 
GOG-218, and preliminary analyses showed no diff erence 
between treatment groups in either study. Here, we 
present the fi nal analysis of mature overall survival data 
from ICON7, together with detailed data about the eff ect 
of bevacizumab according to stage and extent of residual 
disease after primary debulking surgery.
Methods
Study design and participants
The design of this trial has previously been described in 
detail.6 In brief, eligible women with ovarian cancer were 
recruited from 263 centres (a mixture of general hospitals 
and specialist centres) in 11 countries across Europe, 
Canada, Australia, and New Zealand (appendix pp 1–5) 
and were randomly assigned 1:1 in an open-label study to 
receive standard chemotherapy or standard chemo therapy 
with bevacizumab. Eligible patients were aged 18 years or 
Panel: Research in context
Evidence before this study
The primary progression-free survival analysis of the ICON7 trial 
reported signifi cantly improved progression-free survival when 
bevacizumab was added to standard chemotherapy in newly 
diagnosed ovarian cancer. The eff ect was greatest in patients at 
high risk of disease progression. Similar progression-free 
survival fi ndings were reported in the GOG-218 trial.
Added value of this study
In a planned mature analysis of overall survival, no diff erence in 
overall survival was noted between those patients who received 
bevacizumab plus chemotherapy and those who received 
chemotherapy alone. However, in subgroup analyses, improved 
overall survival was noted in patients at high risk of disease 
progression who received bevacizumab compared with those 
who did not.
Implications of all the available evidence
Bevacizumab may have a role in the treatment of patients with 
poor-prognosis ovarian cancer. Future work should address 
questions of treatment duration, targeting, timing, 
re-challenge, and dose fractionation. 
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older; with newly diagnosed epithelial ovarian, fallopian 
tube, or primary peritoneal cancer; an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0–2; 
FIGO 1988 stage IIb–IV or high-risk (grade 3 or clear cell 
histology) stage I–IIa disease; had undergone debulking 
cytoreductive surgery or, in advanced disease, had a biopsy 
with no further surgery planned; and had adequate 
coagulation parameters and liver, renal, and bone marrow 
function. The exclusion criteria were having other tumour 
types, previous systemic therapy, planned surgery, and 
uncontrolled hypertension.
The study protocol was compliant with good clinical 
practice guidelines and the Declaration of Helsinki. 
Ethics approval was obtained in all participating countries 
and where required in all participating centres. 
All patients provided written informed consent.
Randomisation and masking
Randomisation was done centrally by a computer system 
based at the Medical Research Council Clinical Trials Unit 
(London, UK) accessed via the web or telephone. 
Randomisation was done using 1:1 allocation and a 
minimisation algorithm, and was stratifi ed by Gynecologic 
Cancer Intergroup (GCIG) group, a combination of FIGO 
stage and residual disease (stage I–III and ≤1 cm residual 
disease vs stage I–III and >1 cm residual disease vs 
inoperable stage III and stage IV disease) and planned 
interval between surgery and chemo therapy (≤4 weeks or 
>4 weeks). Neither patients nor physicians were masked 
to treatment allocation.
Procedures
Patients received either six 3-weekly cycles of intravenous 
carboplatin (AUC 5 or 6) and paclitaxel (175 mg/m² of 
body surface area), or the same regimen with intravenous 
bevacizumab (7·5 mg/kg of bodyweight) given 
concurrently and continued for 12 further 3-weekly cycles 
(with a duration of bevacizumab exposure of about 
1 year), or until disease progression. To avoid delayed 
wound healing, bevacizumab was omitted at cycle 1 if 
chemotherapy was started within 4 weeks of surgery. 
Bevacizumab cycles omitted for any reason were not 
replaced.
CT scans were done after treatment cycles 3 and 6, and 
then 9 and 12 months after randomisation. Following 
treatment, women were seen every 3 months until the 
end of year 3, every 6 months during years 4 and 5, and 
annually thereafter. Scans continued every 6 months 
until the end of year 3, then as clinically indicated. 
Disease progression was assessed by investigators 
according to RECIST 200011 guidelines, and needed 
radiological or clinical evidence of progression. Cancer 
antigen 125 (CA125) progression alone was insuffi  cient 
to defi ne progressive disease. Following disease 
progression, women were seen every 6 months up until 
year 5, then annually. Quality of life was assessed with 
the European Organisation for Research and Treatment 
of Cancer QLQ-C30 and QLQ-OV28 questionnaires.
Outcomes
The primary outcome of ICON7 was progression-free 
survival, which has been previously reported.6 Secondary 
outcomes were overall survival and safety outcomes of 
adverse events, laboratory results, and worsened ECOG 
performance status. Exploratory outcome measures were 
quality of life, health economics, and translational 
research.
Risk groups were defi ned at the time of the primary 
progression-free survival analysis to enable comparison 
with the GOG-218 study population. They were refi ned 
slightly before database lock for the present analysis in 
accordance with current clinical practice and defi ned 
prospectively in the statistical analysis plan. High risk 
of progression was defi ned as stage IV disease, 
inoperable stage III disease, or suboptimally debulked 
(>1 cm) stage III disease (appendix p 10). To enable 
comparison with previous analyses, results are also 
presented for two other high-risk defi nitions: exclusion 
of inoperable stage III–IV patients, to match the 
previous ICON7 high-risk group; and inclusion of 
patients with 0–1 cm residual tumour, to match the 
GOG-218 population (appendix p 8). Between the 
primary progression-free survival analysis and the 
present analysis, recruiting centres were asked 
(following the GCIG fourth ovarian cancer consensus 
conference statement3) to reclassify patients with up to 
1 cm of residual disease into those with no macroscopic 
residuum or those with macroscopic residuum 
measuring 1 cm or less. The non-high-risk patients 
were defi ned as those who did not meet the criteria for 
high-risk disease.
Figure 1: Trial profi le
*Includes 16 patients last seen more than 6 months before the end of the study. 
†Includes 11 patients last seen more than 6 months before the end of the study.
1528 women enrolled from 263 sites
in 11 countries
764 randomly assigned to receive
standard chemotherapy
764 randomly assigned to receive 
standard chemotherapy plus 
bevacizumab
30 withdrew consent before 
disease progression
12 died before progression
208* did not progress
514 progressed
Further treatment during 
follow-up:
62 none
266 one line
186 two or more lines
 41 received bevacizumab
340 died after progression
22 withdrew consent before 
disease progression
12 died before progression
188† did not progress
542 progressed
Further treatment during 
follow-up:
81 none
269 one line
192 two or more lines
 25 received further bevacizumab
350 died after progression
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Three further patient subgroups of particular interest 
were defi ned: patients with clear cell carcinoma (roughly 
10% of patients because of enriched enrolment—ie, the 
use of less restrictive staging criteria, which meant that 
patients with clear cell carcinoma of any stage were 
eligible); high-risk low-stage patients, with stage I–IIA 
clear cell or grade 3 carcinoma; and low-grade serous 
carcinomas (grade 1).
Statistical analysis
This study was designed and powered to detect 
diff erences in progression-free and overall survival 
between the treatment groups. The analysis of overall 
survival needed 715 deaths to detect a 10-month 
improvement in median survival from 43 to 53 months 
(HR 0·81), with 80% power at a two-sided 5% signifi cance 
level. The progression-free survival analysis needed 
684 disease progression events to show a 5-month 
progression-free survival increase from 18 to 23 months, 
with 90% power and two-sided 5% signifi cance level.
Analysis followed the principle of intention-to-treat and 
included all patients randomly assigned to treatment. 
The primary analysis used an unstratifi ed log-rank test to 
compare overall survival between randomised groups. 
Treatment eff ects were estimated from Cox regression 
analyses when proportional hazards could be assumed. 
With evidence of non-proportionality, fl exible parametric 
survival models12 were used to smooth survival curves 
and estimate survival diff erences during a 5-year period, 
which is the approximate follow-up if patients were 
enrolled midway through the recruitment period and 
remained in follow-up at the study end. Stata version 13.1 
was used for all analyses.
This study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN 91273375.
Role of the funding source
This study was led and funded by the UK Medical 
Research Council Clinical Trials Group. The trial was 
designed by members of the trial management group 
who reviewed and approved the protocol. The trial 
management group included representatives of the 
GCIG participating groups and the funding sources. 
Final decisions about trial conduct were the responsibility 
of chief investigators and funder. The trial management 
group were invited to comment on draft versions of this 
report, but responsibility for the report remained with 
the authors. ADC and AE had full access to all the raw 
data, and ADC had fi nal responsibility for the decision to 
submit for publication.
Results
Between Dec 18, 2006, and Feb 16, 2009, seven GCIG 
groups recruited 1528 women with ovarian cancer from 
263 centres across Europe, Canada, Australia, and New 
Zealand; these women were enrolled and randomly 
assigned to receive standard carboplatin and paclitaxel 
chemotherapy (n=764) or standard chemo therapy plus 
bevacizumab (n=764; fi gure 1). Median follow-up was 
48·9 months (IQR 26·6–56·2), and follow-up ended on 
All patients High-risk patients
Standard therapy (n=764) Bevacizumab (n=764) Standard therapy (n=254) Bevacizumab (n=248)
Overall survival
Follow-up duration (months) 48·6 (24·3–56·0) 48·8 (28·2–56·4) 29·0 (14·1–50·7) 38·9 (21·1–52·5)
Deaths 352 (46%) 362 (47%) 174 (69%) 158 (64%)
Median overall survival (months; 95% CI) 58·6 (53·5–67·5) 58·0 (52·4–66·9) 30·2 (27·0–34·3) 39·7 (36·0–44·2)
Log-rank test p value p=0·85 p=0·03
HR (95% CI) 0·99 (0·85–1·14) 0·78 (0·63–0·97)
Non-proportionality p value* p=0·02 p=0·01
(Restricted) mean survival time (months; 95% CI)† 44·6 (43·2–45·9) 45·5 (44·2–46·7) 34·5 (32·0–37·0) 39·3 (37·0–41·7)
Restricted mean survival time diff erence (95% CI) 0·9 (–0·8 to 2·6) 4·8 (1·5–8·1)
Progression-free survival
Follow-up duration (months) 16·3 (8·8–48·4) 19·4 (12·7–45·3) 10·1 (7·7–18·2) 15·6 (9·9–21·7)
Disease  progression 526 (74%) 554 (73%) 228 (90%) 223 (90%)
Median progression-free survival (months; 95% CI) 17·5 (15·7–18·7) 19·9 (19·1–22·0) 10·5 (9·3–12·0) 16·0 (14·2–17·8)
Log-rank test p value p=0·25 p=0·001
HR (95% CI) 0·93 (0·83–1·05) 0·73 (0·61–0·88)
Non-proportionality p value* p<0·0001 p<0·0001
(Restricted) mean survival time (months; 95% CI)† 27·7 (26·1–29·2) 29·2 (27·7–30·7) 15·9 (14·1–17·7) 20·0 (18·1–21·8)
Restricted mean survival time diff erence (95% CI) 1·6 (–0·6 to 3·7) 4·1 (1·4–6·7)
Data are median (IQR) or n (%), unless otherwise indicated. HRs, p values, and survival time diff erences are for diff erences between the standard therapy and bevacizumab 
groups. HR=hazard ratio. *Grambsch-Therneau test. †Restricted at 5 years. 
Table 1: Primary analysis of overall survival and updated analysis of progression-free survival
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March 31, 2013. Patient baseline characteristics are 
summarised in appendix p 8; the median age of the 
patients was 57 years (IQR 50–64); 1415 (94%) of 1501 
(excluding those with unknown performance status) had 
an ECOG performance status of 0 or 1;  1340 (89%) of 1502 
(excluding those with cancer originating from multiple 
sites) had cancer of ovarian origin; 1054 (69%) had disease 
of serous histology; 175 (11%) had FIGO stage III, IIIA, or 
IIIB disease, and 1071 (70%) stage IIIC or IV disease. 
Following primary surgery, 395 (26%) patients had residual 
disease larger than 1 cm, 369 (24%) had visible disease up 
to 1 cm in diameter, and 734 (48%) had no visible residual 
disease. All randomised patients were included in analyses, 
and patient characteristics were well balanced between the 
groups (appendix p 8). Median follow-up was 48·6 months 
(IQR 24·3–56·0) in the standard chemotherapy group and 
48·8 months (28·2–56·4) in the bevacizumab group, with 
shorter follow-up durations of 29·0 months (14·1–50·7) 
and 38·9 months (21·1–52·5), respectively, for high-risk 
patients.
The patient subgroup at high risk of progression 
consisted of 502 (33%) of 1528 patients. Their median 
age was 60 years (IQR 52–66) and 60 (12%) had cancer of 
primary peritoneal origin (compared with 106 [7%] of all 
enrolled patients overall). Most of the high-risk patients 
(381 [76%]) had serous-type ovarian cancer, and the group 
included 30 (6%) patients who did not undergo debulking 
surgery.
In total, 714 patients (47%) died during the study: 
352 (46%) of those in the chemotherapy group and 
362 (47%) of those in the chemotherapy plus 
bevacizumab group (table 1). The diff erence in overall 
survival between randomised groups was neither 
clinically nor statistically signifi cant (log-rank test 
p=0·85), although non-proportionality was evident 
(p=0·02). Figure 2A shows the Kaplan-Meier survival 
curves for the two groups. Over time, the largest 
absolute diff erence in survival was less than 5%, 
occurring around 2 years after enrolment and favouring 
patients who received bevacizumab (fi gure 2B). Because 
the evidence of non-proportionality renders a hazard 
ratio diffi  cult to interpret, we estimated restricted mean 
survival in each group. Restricted mean survival was 
44·6 months (95% CI 43·2–45·9) for women in the 
chemotherapy group and 45·5 months (44·2–46·7) in 
the chemotherapy plus bevacizumab group (table 1).
Of the 502 high-risk patients, 332 (66%) died, including 
174 (69%) of 254 in the chemotherapy group and 158 (54%) 
Figure 2: Overall survival
(A) Overall survival in all patients. (B) Diff erence in overall survival between all patients in the two groups. (C) Overall survival in high-risk patients. (D) Diff erence in 
overall survival between high-risk patients in the two groups.
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of 248 in the bevacizumab group (table 1). Evidence 
suggested longer overall survival in those who had 
received bevacizumab (p=0·03, fi gure 2C) but evidence of 
non-proportional hazards (p=0·01) meant that the hazard 
ratio was diffi  cult to interpret. Restricted mean overall 
survival time was 39·3 months (95% CI 37·0–41·7) for the 
bevacizumab group and 34·5 months (32·0–37·0) for the 
chemotherapy group (log-rank p=0·03; table 1). The 
absolute diff erence in survival exceeded 10% after 2 years, 
and remained at 4·4% (95% CI –4·1 to 12·9) at 5 years 
(fi gure 2D). However, in non-high-risk patients, the 
restricted mean survival time did not diff er signifi cantly 
between the two treatment groups (49·7 months [95% CI 
48·3–51·1]) in the standard chemotherapy group vs 48·4 
months [47·0–49·9] in the bevacizumab group; p=0·20).
Further analyses of survival by stage, residual disease 
burden, and risk of recurrence showed a benefi t from 
bevacizumab with worsening prognostic factors 
(fi gure 3). Similar patterns were also noted for 
progression-free survival (p=0·014 for stage, p=0·005 for 
high risk; appendix p 12).
No benefi t of bevacizumab was reported for other 
predefi ned poor-prognosis tumour types (table 2). Some 
baseline imbalance was recorded within subgroups, 
which is most likely a consequence of small numbers 
and is unlikely to have aff ected the results (appendix p 9). 
The mortality rate in all three subgroups was lower than 
in the overall trial population, especially in patients with 
low-stage high-grade disease (table 2). No evidence of 
diff erence between treatment groups was recorded 
within these subgroups (table 2).
In our extension of the previously reported quality-of-
life analysis, now including data up to the predefi ned 
timepoint of week 76, in patients without disease 
progression, global quality of life did not diff er between 
those who received standard chemotherapy and those 
receiving bevacizumab at week 76 (p=0·43, appendix 
p 9). In further exploratory analyses, a clinically small 
diff erence was recorded in patients receiving 
bevacizumab who were in the non-high-risk group 
relative to patients not receiving bevacizumab 
(–5·1 points, 95% CI –9·4 to –0·7; p=0·02), whereas a 
Figure 3: Treatment eff ect on overall survival by disease status at enrolment
Hazard ratio (95% CI)
0·2 0·5 1 2
Events (n)/patients (n) Mean overall survival (months)
Bevacizumab group Control group
All patients 0·99  (0·85–1·14)714/1528 45·5 (44·2–46·7) 44·6 (43·2–45·9)
Stage I, II, III (0 cm) 1·23  (0·93–1·62)197/725 51·5 (49·9–53·0) 52·3 (50·8–53·8)
Inoperable 0·52  (0·21–1·27)23/30 34·5 (22·0–47·0) 24·9 (17·7–32·1)
Non-high-risk patients 1·14  (0·93–1·40)382/1026 48·4 (47·0–49·9) 49·7 (48·3–51·1)
High-risk patients 0·78  (0·63–0·97)332/502 39·3 (37·0–41·7) 34·5 (32·0–37·0)
Stage III (>0, ≤1 cm) 0·95  (0·71–1·26) 41·9 (39·1–44·7) 42·6 (39·8–45·4)185/301
Stage III (>1 cm) 0·84  (0·63–1·11) 40·2 (37·3–43·1) 36·1 (32·9–39·3)194/290
Stage IV 0·76  (0·53–1·10) 38·9 (34·9–42·9) 33·5 (29·0–37·9)115/182
Hazard ratio
Interaction p=0·01
Trend p=0·004
Risk status
Disease stage
Clear cell tumours* Low-stage high-grade tumours Low-grade serous tumours
Standard therapy 
(n=77)
Bevacizumab 
(n=82)
Standard therapy 
(n=75)
Bevacizumab 
(n=67)
Standard therapy 
(n=49)
Bevacizumab 
(n=31)
Follow-up duration (months) 52·5 (29·0–57·5) 50·7 (28·2–57·9) 55·3 (49·1–60·6) 55·4 (51·2–61·6) 50·5 (28·2–55·1) 55·3 (47·9–62·0)
Deaths 20 (26%) 24 (29%) 6 (8%) 9 (13%) 13 (27%) 7 (23%)
Log-rank test p value p=0·74 p=0·44 p=0·60
HR (95% CI) 1·09 (0·64–1·88) 1·49 (0·53–4·20) 0·78 (0·31–1·97)
Non-proportionality p value† p=0·58 p=0·002 p=0·07
(Restricted) mean survival 
time (months; 95% CI)‡
48·0 (43·9–52·2) 47·6 (43·6–51·6) 56·2 (51·5–60·9) 57·5 (55·7–59·4) 50·4 (45·6–55·2) 50·5 (43·9–57·0)
Restricted mean survival time 
diff erence (95% CI)
–0·4 (–6·1 to 5·3) 1·3 (–3·7 to 6·4) 0·1 (–7·9 to 8·0)
Data are median (IQR) or n (%), unless otherwise indicated. HRs, p values, and survival time diff erences are for diff erences between the standard therapy and bevacizumab 
groups. *The clear cell tumour group includes some patients with mixed histology. †Grambsch-Therneau test. ‡Restricted at 5 years. 
Table 2: Overall survival in predefi ned subgroups
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small and insignifi cant benefi t (+4·3 points, 
95% CI –4·9 to 13·4; p=0·36) relative to patients not 
receiving bevacizumab was noted in high-risk patients. A 
sensitivity analysis of missing data suggested that these 
fi ndings were robust (appendix p 9).
The primary analysis of progression-free survival was 
previously reported when 759 patients had experienced 
disease progression or died (392 in the standard 
chemotherapy group and 367 in the bevacizumab 
group).6 Since these primary analyses, a further 
321 patients have subsequently progressed or died 
without progression (134 in the standard chemotherapy 
group and 187 in the bevacizumab group) for a total of 
1080 progression events or deaths. The overall 
diff erence in progression-free survival between 
randomised groups was no longer statistically 
signifi cant (table 1; appendix p 11). However, in high-
risk patients, a signi fi cant benefi t remains (p=0·001) 
with strong evidence of non-proportional hazards 
(p<0·0001), and longer mean restricted progression-
free survival in the bevacizumab group than in the 
chemotherapy group (table 1).
Most adverse events that occurred in the trial have been 
previously reported: bevacizumab was associated with an 
increase in grade 1–2 mucocutaneous bleeding (271 
[36%] patients in the bevacizumab group vs 55 [7%] 
patients in the standard chemotherapy group), grade 2 or 
worse hypertension (136 [18%] vs 16 [2%]), grade 3 or 
worse thromboembolic events (51 [7%] vs 23 [3%]), and 
grade 3 or worse gastrointestinal perforations (ten [1%] vs 
three [<1%]).6 During extended follow-up of overall 
survival, one further treatment-related grade 3 event 
(gastrointestinal fi stula in a bevacizumab-treated 
patient), three grade 2 treatment-related events (cardiac 
failure, sarcoidosis, and foot fracture, all in bevacizumab-
treated patients), and one grade 1 treatment-related event 
(vaginal haemorrhage, in a patient treated with standard 
chemotherapy) were also reported.
Discussion
The results of ICON7 show that bevacizumab did not 
improve overall survival in the intention-to-treat 
population of women randomly assigned to receive it in 
conjunction with chemotherapy, although heterogeneity 
of benefi t was observed dependent on residual disease 
burden before treatment. Although the overall diff erence 
between treatment groups was not statistically 
signifi cant, non-proportionality was recorded, despite the 
fact that the magnitude of the change over time was not 
clinically meaningful. However, in a preplanned analysis, 
women at high risk of disease progression had a 
signifi cant improvement in overall survival with the 
addition of bevacizumab to standard chemotherapy. 
A similar improvement in overall survival was also 
reported in high-risk patients (>1 cm residual tumour) in 
GOG-218 (HR 0·73 in ICON7, HR 0·86 in GOG-218), 
with some diff erences as expected because of varying 
post-progression treatment strategies, in particular 
greater use of bevacizumab (ie, more participants 
receiving the drug) in GOG-218 patients. These fi ndings 
are relevant since, in practice, bevacizumab use has 
become focused on the high-risk patient group.
In addition to the contrast between high-risk and non-
high-risk patients, there was a clear association between 
increasing disease severity and a stronger benefi cial 
eff ect of bevacizumab (fi gure 3). To our knowledge, this 
is the fi rst study with bevacizumab to show this trend in 
a single trial. These observations provide a clinical 
framework for the appropriate use of bevacizumab in 
ovarian cancer that is consistent with the biological 
requirement for angiogenesis in growing tumours, and a 
hypothetical framework to explain this eff ect biologically. 
Our data suggest that a residual physical tumour burden, 
presumably producing VEGF, is necessary to enable 
bevacizumab to exert its eff ect on the tumour 
microenvironment. Other trials in ovarian cancer have 
also reported an overt benefi t in women with a 
measurable (higher) disease burden following 
recurrence, in both platinum-sensitive7 and platinum-
resistant settings.8
These fi nal results complement the fi ndings of the 
earlier primary progression-free survival analysis,6 with a 
benefi t of bevacizumab recorded in women with 
advanced-stage suboptimally debulked disease. 
The magnitude and duration of benefi t in this group is 
both clinically and statistically signifi cant. The primary 
progression-free survival analyses also showed similar 
outcomes in GOG-218 patients and the high-risk patient 
group of ICON7.5,6 The updated progression-free survival 
analysis reported here showed a reduced overall eff ect, 
with greater elapsed time from treatment with 
bevacizumab, but the earlier results remain the primary 
pre-specifi ed analysis.
Our data also identify patients who might not benefi t 
from bevacizumab in the fi rst-line setting. Women with 
early-stage (FIGO stage I/II) disease, even if judged to be 
high risk on the basis of grade or clear cell histology, do 
not seem to benefi t. Women with optimally debulked 
(<1 cm) stage III disease also had no benefi t. Furthermore, 
a small reduction in overall quality of life was recorded in 
non-high-risk patients treated with bevacizumab. 
Our trial included patients with all stages of newly 
diagnosed epithelial ovarian, fallopian tube, and primary 
peritoneal cancer for whom postoperative chemotherapy 
would usually be indicated. It also included 30 patients in 
whom primary, and subsequent, debulking surgery was 
regarded as unlikely to be in the patient’s best interests.
Three subgroups based on tumour type were also 
predefi ned: clear cell, low-grade serous, and high-risk 
low-stage cancer. Women with clear cell carcinoma 
comprised 10% of the study population. This histology 
was previously thought to confer a substantially worse 
outcome than other tumour subtypes but these patients 
did surprisingly well in our trial, with a 72% survival 
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after a median of 51 months’ follow-up, with no benefi t 
from bevacizumab. Patients with low-grade serous 
cancer also did not benefi t from the addition of 
bevacizumab, although a major limitation of this 
assessment is the absence of central pathology review 
for these tumours. Patients with low-stage high-risk 
tumours also did not benefi t from the addition of 
bevacizumab. For all three subgroup analyses, the 
numbers of patients were small and statistical power to 
detect diff erences was low.
To refl ect on the choice of outcome measures for the 
ICON7 trial is pertinent. The primary outcome measure 
was progression-free survival, but the trial was also 
a-priori structured to assess overall survival. To assess 
this outcome measure needed a further 3 years of follow-
up after the primary progression-free survival analysis, 
but also simplifi ed aspects of trial design, such as 
placebo control and independent masked radiology 
review, which are essential when progression-free 
survival is the only outcome measure. The primary 
analysis in 2011 showed a signifi cant progression-free 
survival benefi t in the intention-to-treat population, 
which was most pronounced in women at high risk of 
progression.6 Over time, the eff ect closely followed 
bevacizumab treatment, with the maximum benefi t 
coinciding precisely with duration of treatment 
(appendix p 11). Notably, the overall survival diff erence 
outlasts the duration of bevacizumab exposure and 
points to a durable benefi t in the high-risk group 
(fi gure 2D), raising the possibility of additional benefi t to 
high-risk patients from further extension of treatment 
duration, which is the subject of ongoing research in the 
BOOST trial (NCT01462890). Following disease 
progression in ICON7, the pattern of further treatment 
was similar in both randomised groups, with little use of 
further bevacizumab in either group.
Questions about the optimum timing of bevacizumab 
therapy in the trajectory of a woman’s disease remain. 
Should it be considered at initial presentation, time of 
platinum-sensitive recurrence, or after the development 
of platinum resistance? Bevacizumab has shown a 
signifi cant progression-free survival benefi t in all these 
settings,5–8 and an overall survival benefi t in some settings 
too.6,13,14 Our data strongly support early use of 
bevacizumab, based on risk and disease burden. Whether 
or not bevacizumab can be used beyond progression in 
this indication, and whether or not treatment can be 
repeated, remains an intriguing question that is being 
addressed in the MITO16MANGO2b trial (NCT01802749); 
with studies in colorectal cancer15 and breast cancer16 
having already provided evidence of benefi t.
From a societal perspective, there are strong and 
sometimes opposing views about the costs and cost–
benefi t ratio of bevacizumab. The JGOG-316 trial17 
reported a similar overall survival benefi t without 
bevacizumab from the use of weekly paclitaxel, whereas 
GOG-26218 suggests that the eff ect of bevacizumab may 
be attenuated by such a strategy. Full economic analyses 
related to our trial are ongoing and will be reported 
separately. Interestingly, the small reduction in quality 
of life associated with bevacizumab that was reported 
after 54 weeks19 was smaller still by week 76 and was not 
statistically signifi cant. The ability to predict which 
patients will benefi t most is clearly important and could 
have the power to change the cost-eff ectiveness of 
treatment substantially by not treating patients with 
little chance of benefi t. Our data suggest a simple and 
pragmatic clinical algorithm based on residual disease. 
Many studies are underway to identify a biomarker 
signature of response or resistance in patients in our 
trial. Collinson and colleagues20 and Backen and 
colleagues21 have presented biomarker strategies with 
potentially predictive approaches, whereas Gourley and 
colleagues22 have reported that bevacizumab might 
disadvantage women with an immunologically active 
subtype and Winterhoff  and coworkers have reported 
benefi t for women with mesenchymal-subtype disease.23 
These fi ndings all need to be validated in independent 
datasets.
The addition of bevacizumab to chemotherapy is an 
important step forward in integrating biological agents 
with conventional chemotherapy in ovarian cancer. This 
trial provides evidence of a benefi t in poor-prognosis 
patients. Future studies will refi ne important questions 
of biological prediction, duration, and rechallenge.
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